CareCloud Inc (CCLDO) 股票分析

公司概述

CareCloud, Inc. operates as a healthcare information technology enterprise that delivers technology-enabled business solutions, Software-as-a-Service offerings, and related business services primarily to healthcare providers and hospitals within the United States. The company functions within the Healthcare sector and specifically targets the Health Information Services industry, positioning itself to support the digitization and operational efficiency of medical practices. In terms of scale, CareCloud, Inc. employs approximately 3,650 individuals and reports a trailing twelve-month revenue of $120.50 million, while its market capitalization is listed as N/A in current data. The absence of a disclosed market cap figure alongside the reported revenue suggests that valuation metrics may rely on alternative metrics such as enterprise value or price-to-book ratios rather than traditional equity market capitalization, indicating a specific valuation structure for this asset class. The employee count of 3,650 reflects a substantial operational footprint required to support its SaaS model and extensive service delivery network across the healthcare landscape.

财务健康

The company reported a trailing twelve-month revenue of $120.50 million with a corresponding net income of $3.89 million and an EBITDA of $16.39 million. The significant gap between the $120.50 million in revenue and the $3.89 million in net income reveals a cost structure where operating expenses and taxes consume approximately 96.7% of top-line revenue before arriving at the bottom line. Despite the lower net income, the EBITDA stands at $16.39 million, generating $18.23 million in free cash flow, which provides the company with significant financial flexibility to fund operations or return capital without relying on external financing. The gross margin sits at 46.5%, indicating that the company retains nearly half of its revenue after direct costs, while the operating margin of 9.1% and profit margin of 9.0% demonstrate that general and administrative expenses, along with taxes, further compress the bottom line. The balance sheet shows $3.12 million in cash against $4.28 million in debt, resulting in a debt-to-equity ratio of 7.20, which indicates a leveraged capital structure where debt obligations significantly outweigh equity holdings. The current ratio of 1.05 suggests that the company's current assets just barely cover its current liabilities, pointing to a tight but manageable short-term liquidity position. Return on equity is reported at 19.8% while return on assets is 9.0%, indicating that management is highly effective at generating returns on the shareholders' equity but that the asset base generates lower returns relative to the total capital employed.

估值评估

Trailing P/E and forward P/E ratios are both listed as N/A, meaning that traditional earnings-based valuation multiples cannot be calculated due to the lack of reported net income data or forward projections in the available metrics. Instead, the price-to-book ratio is 18.60, which indicates that the market values the company's equity at a substantial premium of over 18 times its net asset book value. The price-to-sales ratio is N/A, but the EV/EBITDA multiple stands at 67.69, a figure that suggests a very high valuation relative to cash flows generated before interest, taxes, depreciation, and amortization. The 52-week high is $26.75 and the 52-week low is $17.30, providing a trading range within which the stock has fluctuated over the past year. The beta value of 1.83 indicates that the stock price is expected to be approximately 83% more volatile than the broader market, reflecting higher systematic risk for investors in the healthcare technology sector. The high EV/EBITDA of 67.69 combined with the elevated price-to-book ratio underscores the market's willingness to pay a premium for the company's intangible assets or future growth potential despite the high leverage.

Growth & Income

Revenue growth for the trailing twelve months is 21.9% year-over-year, whereas earnings growth is listed as N/A, implying that earnings are not currently being tracked or reported in a manner that allows for a direct growth rate comparison. The dividend yield stands at 8.4%, which is a substantial return on capital for income-focused investors, while the payout ratio is N/A, preventing a direct assessment of sustainability against current earnings. Given the N/A payout ratio and the specific context of the data, the high dividend yield suggests a significant portion of capital is returned to shareholders, though the sustainability depends on the underlying cash flow generation relative to the 7.20 debt-to-equity leverage. The overall growth and income profile presents a high-yield scenario coupled with strong revenue expansion, although the lack of explicit earnings growth data limits the ability to confirm if profitability is keeping pace with top-line sales.